Today: 21 May 2026
NIO stock jumps 4.7% after CEO sets Q4 sales bar — what to watch next
30 December 2025
2 mins read

NIO stock jumps 4.7% after CEO sets Q4 sales bar — what to watch next

NEW YORK, December 30, 2025, 02:27 ET — Market closed

  • NIO ended Monday up 4.7% at $5.34, extending a three-session rise on heavy volume.
  • CEO William Li flagged fourth-quarter vehicle sales above 30 billion yuan, lifting sentiment on demand and pricing.
  • Traders are watching U.S. economic releases and Fed minutes due Tuesday, alongside upcoming delivery signals.

NIO Inc (NIO.N) shares rose 4.71% to $5.34 on Monday, extending a three-session rise even as U.S. stocks slipped. CEO William Li said fourth-quarter vehicle sales “should exceed 30 billion yuan” at a customer event in China, TipRanks reported. Volume climbed to 68.3 million shares and the stock remains about 33% below its 52-week high of $8.02; TipRanks noted Tesla and Li Auto fell on the day.

The read-through for investors is whether Nio can finish the year with momentum while China’s EV makers fight for market share and pricing power. Nio has said it expects to break even in the fourth quarter, a milestone that would ease concerns about cash burn and funding needs.

Li’s sales comment also lands as portfolios head into year-end, when traders tend to cut risk quickly on any sign demand is wobbling. A strong quarter would give the company more room to fund new models and distribution without leaning as hard on incentives.

In its latest monthly update, Nio said it delivered 36,275 vehicles in November, up 76.3% from a year earlier, bringing cumulative deliveries to 767,531 vehicles. Monthly deliveries are a key barometer for EV makers because they provide a near real-time demand check.

Separate recent company news has also kept attention on Nio’s flagship lineup. The company delivered its 40,000th third-generation ES8 and announced the milestone on its social media, CnEVPost reported.

From a trading standpoint, Nio has been hovering around the $5 level. The stock traded between $5.06 and $5.38 in Monday’s session, according to LSEG data.

That keeps $5.00 in focus as near-term support, with the prior session’s high near $5.38 as the first upside marker. A move through that zone would start to chip away at the longer slide from October’s $8.02 peak.

Investors will look for management to back up the sales talk with firmer signals on margins — the profit left after production costs — and on how quickly newer models can scale without heavy discounting.

Before the next session, broader risk appetite may hinge on a cluster of U.S. releases and central-bank communication. The S&P Case-Shiller home price index is due at 9:00 a.m. ET and the Chicago PMI — a survey gauge of business activity — is scheduled for 9:45 a.m. ET, followed by the release of the Federal Reserve’s meeting minutes at 2:00 p.m. ET.

Minutes are the detailed record of the Fed’s rate-setting meeting, and any shift in tone on interest rates can jolt growth stocks and higher-beta names like EV makers. That leaves Tuesday’s tape sensitive to headlines well beyond autos.

On the company calendar, the next major catalyst is its quarterly report. Zacks expects Nio’s next earnings release in mid-March, putting delivery trends and margin progress into sharper focus as 2026 begins.

Stock Market Today

  • Scotiabank Shares Showing 32% Undervaluation at C$108 Amid Strong Returns
    May 20, 2026, 10:05 PM EDT. Scotiabank (TSX:BNS) stock has rallied to around C$108.50, delivering a 59.4% return over the past year and nearly 79% over five years highlighting strong performance. Despite this, valuation models suggest substantial remaining upside. Simply Wall St's Excess Returns analysis estimates the bank's intrinsic value at approximately C$160 per share, indicating it is 32.2% undervalued compared to current prices. This model calculates excess returns by comparing the bank's return on equity to its cost of equity, reflecting efficient shareholder profit generation. Investors are closely watching key fundamentals including balance sheet resilience and dividend yield as Scotiabank navigates evolving interest rate environments. The stock's valuation score of 4 out of 6 suggests moderate confidence among analysts that price gains can continue.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision
Previous Story

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Bitcoin ATM scam costs Nebraska couple $250,000 as crypto kiosk fraud draws fresh warnings
Next Story

Bitcoin ATM scam costs Nebraska couple $250,000 as crypto kiosk fraud draws fresh warnings

Go toTop